New Zealand markets open in 1 hour 50 minutes
  • NZX 50

    +60.49 (+0.54%)

    +0.0018 (+0.29%)

    +87.70 (+1.20%)
  • OIL

    +0.07 (+0.06%)
  • GOLD

    +3.00 (+0.16%)

IMPLANET Announces Its 2022 Financial Calendar

·2-min read

BORDEAUX, France & BOSTON, January 24, 2022--(BUSINESS WIRE)--Regulatory News:

IMPLANET (Paris:ALIMP) (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specialized in vertebral implants, today announces its schedule for the publication of financial information for 2022Etats-Unis de son expansion commerciale aux Etats-Unis,.



2021 Full-Year Results

March 15, 2022

2022 First-Quarter Revenue

April 19, 2022

Annual General Meeting

April 26, 2022

2022 First-Half Revenue

July 11, 2022

2022 First-Half Results

September 20, 2022

2022 Third-Quarter Revenue

October 18, 2022

(*): These dates can be subject to modifications. Press releases will be published after market close.

Upcoming financial event:
2021 Full-Year Results, on March 15, 2022 after market close.


Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its activity revolves around a comprehensive innovative solution for improving the treatment of spinal pathologies (JAZZ®) complemented by the product range offered by Orthopaedic & Spine Development (OSD), acquired in May 2021 (thoraco-lumbar screws, cages and cervical plates). Implanet’s tried-and-tested orthopedic platform is based on the traceability of its products. Protected by four families of international patents, JAZZ® has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States, the CE mark in Europe and ANVISA approval in Brazil. IMPLANET employs 29 staff and recorded a consolidated revenue of €6.1 million in 2021. Based near Bordeaux in France, IMPLANET opened a US subsidiary in Boston in 2013. IMPLANET is listed on the Euronext Growth market in Paris. For further information, please visit

The Company would like to remind readers that the table for monitoring the equity line (OCA, BSA) and the number of shares outstanding is available on its website:

View source version on


Ludovic Lastennet, CEO
David Dieumegard, CFO
Tel.: +33 (0)5 57 99 55 55

Investor Relations
Mathilde Bohin
Nicolas Fossiez
Tel.: +33 (0)1 44 71 94 94

Media Relations
Nicolas Merigeau
Tel.: +33 (0)1 44 71 94 94

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting